Drug
Ecopipam clinical trials
Also written PSYRX101 and SCH 39166.
- studies test it
- 19
- open now
- 0
- in phase 3
- 4
- first study started
- 2010
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 8
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Emalex Biosciences Inc. (15) · Psyadon Pharma (2) · William Ondo, MD (1) · Gerald Maguire, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ecopipam is read from its arms, and is right about nine times in ten.
Testing it · 19
- Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)CompletedPhase 2Emalex Biosciences Inc.NCT04492956Written as Ecopipam
- A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's DisorderActive, not recruitingPhase 3Emalex Biosciences Inc.NCT06021522Written as Ecopipam
- Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and AdultsCompletedPhase 3Emalex Biosciences Inc.NCT05615220Written as Ecopipam Hydrochloride
- Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 YearsCompletedPhase 2Emalex Biosciences Inc.NCT02102698Written as Ecopipam
- Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific AntagonistCompletedPhase 1/2William Ondo, MDNCT03218969Written as Ecopipam
- Food-effect Study of Ecopipam PharmacokineticsCompletedPhase 1Emalex Biosciences Inc.NCT06669091Written as Ecopipam tablet
- Drug Interaction StudyCompletedPhase 1Emalex Biosciences Inc.NCT06194864Written as Ecopipam
- Clinical Study to Determine if Ecopipam Can Reduce Urges to GambleCompletedPhase 2Emalex Biosciences Inc.NCT01215357Written as Ecopipam
- Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan DiseaseTerminatedPhase 3Emalex Biosciences Inc.NCT01751802Written as Ecopipam
- Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of EcopipamCompletedPhase 1Emalex Biosciences Inc.NCT01408394Written as Ecopipam immediate release form
- Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label ExtensionCompletedPhase 2Emalex Biosciences Inc.NCT04114539Written as Ecopipam
- Ecopipam Tablets to Study Tourette's Syndrome in Children and AdolescentsCompletedPhase 2Emalex Biosciences Inc.NCT04007991Written as Ecopipam
- Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac RepolarizationCompletedPhase 1Emalex Biosciences Inc.NCT05841160Written as Ecopipam Hydrochloride
- Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and TransportCompletedPhase 1Emalex Biosciences Inc.NCT05334108Written as Ecopipam
- Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male SubjectsCompletedPhase 1Emalex Biosciences Inc.NCT04881955Written as [14C]-Ecopipam
- Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active MetaboliteCompletedPhase 1Emalex Biosciences Inc.NCT04902105Written as ecopipam HCL
- Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).Status unknownPhase 2/3Gerald Maguire, MDNCT02909088Written as Ecopipam 50mg
- Ecopipam Treatment of Tourette SyndromeCompletedPhase 1/2Psyadon PharmaNCT01244633Written as Ecopipam
- Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan DiseaseCompletedPhase 1Psyadon PharmaNCT01065558Written as Ecopipam
Codes
What other systems call ecopipam · ClinicalTrials.gg INT003403
- MeSH (NLM) C058081ecopipamConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0X748O646KECOPIPAMConfirmed FDA, NLM, Wikidata
- Wikidata Q5333851ecopipamConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74188EcopipamOne source FDA
- DrugBank DB12273One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C058081 | ecopipam | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0X748O646K | ECOPIPAM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5333851 | ecopipam | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74188 | Ecopipam | One source FDA |
| DrugBank | DB12273 | — | One source Wikidata |
Also registered as ecopipam hydrochloride (UNII 5X1J3190JI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.